AbstractIn a phase II/III clinical trial intraperitoneal (i.p.) administration of a group C adenovirus vector (Ad5) caused bowel adhesion formation, perforation and obstruction. However, we had found that i.p. group B, in contrast to group C adenoviruses, did not cause adhesions in nude BALB/c ovarian cancer models, prompting further investigation. Ex vivo, group B Ad11 caused lower inflammatory responses than Ad5 on BALB/c peritoneal macrophages. In vivo, i.p. Ad11 triggered short-term cytokine and cellular responses equal to Ad5 in both human CD46-positive and -negative mice. In contrast, in a long-term study of repeated i.p. administration, Ad11 caused no/mild, whereas Ad5 induced moderate/severe adhesions and substantial liver toxicity ...
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses (Ads) ...
AbstractThe efficiency of cancer gene therapy with recombinant adenoviruses based on serotype 5 (Ad5...
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene - Deleted adenovirus ONYX-015 (dl15...
AbstractIn a phase II/III clinical trial intraperitoneal (i.p.) administration of a group C adenovir...
The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by i...
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapie...
The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fi...
AbstractHuman adenovirus type 5 (Ad5) has been the most popular platform for the development of onco...
Ovarian cancer is the leading cause of gynecological disease death despite advances in medicine. The...
Adenoviruses have been clinically tested as anticancer therapies but their utility has been severely...
PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, viru...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
Ovarian cancer is the deadliest gynaecological cancer, with less than half of patients surviving fiv...
Gene and virotherapy of ovarian cancer, using type 5 adenovirus (Ad5), has demonstrated good activit...
Oncolytic adenoviruses show promise as a cancer treatment. However, they generate acute inflammatory...
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses (Ads) ...
AbstractThe efficiency of cancer gene therapy with recombinant adenoviruses based on serotype 5 (Ad5...
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene - Deleted adenovirus ONYX-015 (dl15...
AbstractIn a phase II/III clinical trial intraperitoneal (i.p.) administration of a group C adenovir...
The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by i...
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapie...
The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated into the type-5 fi...
AbstractHuman adenovirus type 5 (Ad5) has been the most popular platform for the development of onco...
Ovarian cancer is the leading cause of gynecological disease death despite advances in medicine. The...
Adenoviruses have been clinically tested as anticancer therapies but their utility has been severely...
PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, viru...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
Ovarian cancer is the deadliest gynaecological cancer, with less than half of patients surviving fiv...
Gene and virotherapy of ovarian cancer, using type 5 adenovirus (Ad5), has demonstrated good activit...
Oncolytic adenoviruses show promise as a cancer treatment. However, they generate acute inflammatory...
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses (Ads) ...
AbstractThe efficiency of cancer gene therapy with recombinant adenoviruses based on serotype 5 (Ad5...
Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene - Deleted adenovirus ONYX-015 (dl15...